BioSpace News Archive

Precision Optics Corporation, Inc. (NASDAQ: POCI) today announced Dr. Joe Forkey, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2023 Investor Conference, taking place virtually on May 18, 2023.

Debiopharm (www.debiopharm.com) today announced the start of its open-label Phase 1/2 study evaluating Debio 0123, a brain-penetrant and highly selective WEE1 inhibitor, in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.

The escalating battle between Claudin 6 immunotherapies from Amgen, BioNTech and Context Therapeutics, and CLDN6 antibody-drug-conjugates from Daiichi-Sankyo and TORL BioTherapeutics will be a highlight of the upcoming 2023 American Society of Clinical Oncology Annual Meeting, taking place on June 2-6, 2023, in Chicago, IL.

As part of National Women’s Health Week, Evidation and Myovant Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd. announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Plandai Biotechnology, Inc. announce the completion of a share exchange agreement whereby PLPL shall acquire one hundred percent of the issued and outstanding ByoPlanet Interests and ByoPlanet’s fixed tangible and intangible assets in exchange for all authorized, issued, and outstanding PLPL Preferred Common Shares and Common Stock.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production while increasing our sustainability efforts.

The annual general meeting was held in AlzeCure Pharma AB.

AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023).

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two virtual investor conferences in May.